These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8903483)

  • 1. Glucose-regulated stresses induce resistance to camptothecin in human cancer cells.
    Tomida A; Yun J; Tsuruo T
    Int J Cancer; 1996 Nov; 68(3):391-6. PubMed ID: 8903483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II.
    Yun J; Tomida A; Nagata K; Tsuruo T
    Oncol Res; 1995; 7(12):583-90. PubMed ID: 8704275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
    Kim HD; Tomida A; Ogiso Y; Tsuruo T
    J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
    Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
    Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress.
    Yamada M; Tomida A; Yun J; Cai B; Yoshikawa H; Taketani Y; Tsuruo T
    Cancer Chemother Pharmacol; 1999; 44(1):59-64. PubMed ID: 10367750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
    Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
    PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures.
    Chen AY; Yu C; Bodley A; Peng LF; Liu LF
    Cancer Res; 1993 Mar; 53(6):1332-7. PubMed ID: 8383008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors.
    Tomida A; Tsuruo T
    Anticancer Drug Des; 1999 Apr; 14(2):169-77. PubMed ID: 10405643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
    Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.
    Larsen AK; Gilbert C; Chyzak G; Plisov SY; Naguibneva I; Lavergne O; Lesueur-Ginot L; Bigg DC
    Cancer Res; 2001 Apr; 61(7):2961-7. PubMed ID: 11306474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells.
    Tomida A; Suzuki H; Kim HD; Tsuruo T
    Oncogene; 1996 Dec; 13(12):2699-705. PubMed ID: 9000144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
    Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
    Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.